Annual Reports in Medicinal Chemistry

Klappentext Annual Reports in Medicinal Chemistry provides timely and critical reviews of important topics in medicinal chemistry together with an emphasis on emerging topics in the biological sciences, which are expected to provide the basis for entirely new future therapies. Zusammenfassung Provides critical reviews of important topics in medicinal chemistry together with an emphasis on topics in the biological sciences! which are expected to provide the basis for entirely new future therapies. Inhaltsverzeichnis Personal Essay Reflections on Medicinal Chemistry at Merck, West Point Paul S. Anderson My Path in Seeking New Medicines Peter R. Bernstein Tales of Drug Discovery M. Ross Johnson I. Central Nervous System Diseases Section Editor: Albert J. Robichaud; Sage Therapeutics, Inc. Cambridge, Massachusetts Recent Developments in Targeting Neuroinflammation in Disease Allen T. Hopper, Brian M. Campbell, Henry Kao, Sean A. Pintchovski and Roland G. W. Staal Secretase Inhibitors and Modulators as a Disease Modifying Approach Against Alzheimer's Disease Harrie J. M. Gijsen and François P. Bischoff mGluR2 Activators and mGluR5 Blockers Advancing in the Clinic for Major CNS Disorders Sylvain Célanire, Guillaume Duvey, Sonia Poli and Jean-Philippe Rocher NMDA Antagonists of GluN2B Subtype and Modulators of GluN2A, GluN2C and GluN2D Subtypes - Recent Results and Developments Kamalesh B. Ruppa, Dalton King and Richard Olson Recent Advances in the Development of PET and SPECT Tracers for Brain Imaging Lei Zhang and Anabella Villalobos II. Cardiovascular and Metabolic Diseases Section Editor: Andy Stamford, Merck Research Laboratories, Kenilworth, New Jersey Case History: EliquisTM (Apixaban), a Potent and Selective Inhibitor of Coagulation Factor Xa for the Prevention and Treatment of Thrombotic Diseases Donald J. P. Pinto, Pancras C. Wong, Robert M. Knabb and Ruth R. R. Wexler AMPK Activation in Health and Disease Iyassu K. Sebhat and Robert W. Myers Type-2 Diabetes and Associated Co-Morbidities as an Inflammatory Syndrome Juan C. Jaen, Jay P. Powers and Tim Sullivan Beyond PPARs & Metformin: New Insulin Sensitizers for the Treatment of Type 2 Diabetes Philip A. Carpino and David Hepworth III. Inflammatory Pulmonary and Gastrointestinal Diseases Section Editor: David S. Weinstein, Bristol-Myers Squibb R&D, Princeton, New Jersey Recent Advances in the Discovery and Development of Sphingosine-1-Phosphate-1 Receptor Agonists Alaric J. Dyckman Bifunctional Compounds for the Treatment of COPD Gary Phillips and Michael Salmon Inflammatory Targets for the Treatment of Atherosclerosis Robert O. Hughes, Alessandra Bartolozzi and Hidenori Takahashi IV. Oncology Section Editor: Shelli R. McAlpine, School of Chemistry, University of New South Wales, Sydney, Australia Nanotechnology Therapeutics in Oncology - Recent Developments and Future Outlook Paul F. Richardson Small-Molecule Antagonists of Bcl-2 Family Proteins Sean P. Brown and Joshua P. Taygerly Notch Pathway Modulators as Anti-Cancer Chemotherapeutics Vibhavari Sail and M. Kyle Hadden Anaplastic Lymphoma Kinase (ALK) Inhibitors for the Treatment of ALK-Positive Cancers Kazutomo Kinoshita, Nobuhiro Oikawa and Takuo Tsukuda V. Infectious Diseases Section Editor: John Primeau, Westford, Massachusetts Recent Advances in the Discovery of Dengue Virus ...

List of contents

Personal Essay

1. Reflections on Medicinal Chemistry at Merck, West Point
Paul S. Anderson


2. My Path in Seeking New Medicines
Peter R. Bernstein


3. Tales of Drug Discovery
M. Ross Johnson
I. Central Nervous System Diseases
Section Editor: Albert J. Robichaud; Sage Therapeutics, Inc. Cambridge, Massachusetts


4. Recent Developments in Targeting Neuroinflammation in Disease
Allen T. Hopper, Brian M. Campbell, Henry Kao, Sean A. Pintchovski and Roland G. W. Staal


5. Secretase Inhibitors and Modulators as a Disease Modifying Approach Against Alzheimer's Disease
Harrie J. M. Gijsen and François P. Bischoff


6. mGluR2 Activators and mGluR5 Blockers Advancing in the Clinic for Major CNS Disorders
Sylvain Célanire, Guillaume Duvey, Sonia Poli and Jean-Philippe Rocher


7. NMDA Antagonists of GluN2B Subtype and Modulators of GluN2A, GluN2C and GluN2D Subtypes - Recent Results and Developments
Kamalesh B. Ruppa, Dalton King and Richard Olson


8. Recent Advances in the Development of PET and SPECT Tracers for Brain Imaging
Lei Zhang and Anabella Villalobos
II. Cardiovascular and Metabolic Diseases
Section Editor: Andy Stamford, Merck Research Laboratories, Kenilworth, New Jersey


9. Case History: Eliquis^TM (Apixaban), a Potent and Selective Inhibitor of Coagulation Factor Xa for the Prevention and Treatment of Thrombotic Diseases
Donald J. P. Pinto, Pancras C. Wong, Robert M. Knabb and Ruth R. R. Wexler


10. AMPK Activation in Health and Disease
Iyassu K. Sebhat and Robert W. Myers


11. Type-2 Diabetes and Associated Co-Morbidities as an Inflammatory Syndrome
Juan C. Jaen, Jay P. Powers and Tim Sullivan


12. Beyond PPARs & Metformin: New Insulin Sensitizers for the Treatment of Type 2 Diabetes
Philip A. Carpino and David Hepworth
III. Inflammatory Pulmonary and Gastrointestinal Diseases
Section Editor: David S. Weinstein, Bristol-Myers Squibb R&D, Princeton, New Jersey


13. Recent Advances in the Discovery and Development of Sphingosine-1-Phosphate-1 Receptor Agonists
Alaric J. Dyckman


14. Bifunctional Compounds for the Treatment of COPD
Gary Phillips and Michael Salmon


15. Inflammatory Targets for the Treatment of Atherosclerosis
Robert O. Hughes, Alessandra Bartolozzi and Hidenori Takahashi
IV. Oncology
Section Editor: Shelli R. McAlpine, School of Chemistry, University of New South Wales, Sydney, Australia


16. Nanotechnology Therapeutics in Oncology - Recent Developments and Future Outlook
Paul F. Richardson


17. Small-Molecule Antagonists of Bcl-2 Family Proteins
Sean P. Brown and Joshua P. Taygerly


18. Notch Pathway Modulators as Anti-Cancer Chemotherapeutics
Vibhavari Sail and M. Kyle Hadden


19. Anaplastic Lymphoma Kinase (ALK) Inhibitors for the Treatment of ALK-Positive Cancers
Kazutomo Kinoshita, Nobuhiro Oikawa and Takuo Tsukuda
V. Infectious Diseases
Section Editor: John Primeau, Westford, Massachusetts


20. Recent Advances in the Discovery of Dengue Virus Inhibitors
Jeremy Green, Upul Bandarage, Kate Luisi and Rene Rijnbrand


21. Non Fluoro-Quinolone Based Inhibitors of Mycobacterial Type II Topoisomerase as Potential Therapeutic Agents for TB
Pravin S. Shirude and Shahul Hameed


22. HCV Inhibition Mediated through the Nonstructural Protein 5A (NS5A) Replicati

Report

This series is one of the very few annual publications which justify the title of an absolute must for the pharmacologist, chemist, or physician who is interested in the chemistry of drug development." --Enzymologia

Product details

• Authors: John E. Macor, John E. (EDT) Macor
• Assisted by: Manoj C. Desai (Editor), Manoj E. Desai (Editor), John E Macor (Editor), John E. Macor (Editor), Macor John E. (Editor of the series)
• Publisher: Academic Press London
• Languages: English
• Product format: Paperback / Softback
• Released: 01.10.2012
• EAN: 9780123964922
• ISBN: 978-0-12-396492-2
• No. of pages: 472
• Series: Annual Reports in Medicinal Ch; Annual Reports in Medicinal Chemistry; Annual Reports in Medicinal Ch; Annual Reports in Medicinal Chemistry
• Subjects: Natural sciences, medicine, IT, technology > Technology > Chemical engineering; REFERENCE / Yearbooks & Annuals, MEDICAL / Pharmacology, REFERENCE / Almanacs, Pharmacology, Pharmaceutical technology, Yearbooks, annuals, almanacs, Pharmaceutical chemistry and technology, TECHNOLOGY & ENGINEERING / Pharmaceutical